100 related articles for article (PubMed ID: 29803728)
1. Kava analogues as agents for treatment of periodontal diseases: Synthesis and initial biological evaluation.
Cai B; Panek JS; Amar S
Bioorg Med Chem Lett; 2018 Sep; 28(16):2667-2669. PubMed ID: 29803728
[TBL] [Abstract][Full Text] [Related]
2. Kava-241 reduced periodontal destruction in a collagen antibody primed Porphyromonas gingivalis model of periodontitis.
Alshammari A; Patel J; Al-Hashemi J; Cai B; Panek J; Huck O; Amar S
J Clin Periodontol; 2017 Nov; 44(11):1123-1132. PubMed ID: 28746780
[TBL] [Abstract][Full Text] [Related]
3. Identification of a Kavain Analog with Efficient Anti-inflammatory Effects.
Huck O; Han X; Mulhall H; Gumenchuk I; Cai B; Panek J; Iyer R; Amar S
Sci Rep; 2019 Sep; 9(1):12940. PubMed ID: 31506483
[TBL] [Abstract][Full Text] [Related]
4. Reduction of Articular and Systemic Inflammation by Kava-241 in a Porphyromonas gingivalis-Induced Arthritis Murine Model.
Huck O; You J; Han X; Cai B; Panek J; Amar S
Infect Immun; 2018 Sep; 86(9):. PubMed ID: 29914930
[TBL] [Abstract][Full Text] [Related]
5. Radical-scavenging and Anti-inflammatory Activity of Quercetin and Related Compounds and Their Combinations Against RAW264.7 Cells Stimulated with Porphyromonas gingivalis Fimbriae. Relationships between Anti-inflammatory Activity and Quantum Chemical Parameters.
Murakami Y; Kawata A; Ito S; Katayama T; Fujisawa S
In Vivo; 2015; 29(6):701-10. PubMed ID: 26546527
[TBL] [Abstract][Full Text] [Related]
6. Long-term evaluation of oral gavage with periodontopathogens or ligature induction of experimental periodontal disease in mice.
de Molon RS; Mascarenhas VI; de Avila ED; Finoti LS; Toffoli GB; Spolidorio DM; Scarel-Caminaga RM; Tetradis S; Cirelli JA
Clin Oral Investig; 2016 Jul; 20(6):1203-16. PubMed ID: 26411857
[TBL] [Abstract][Full Text] [Related]
7. Liver X receptors contribute to periodontal pathogen-elicited inflammation and oral bone loss.
Huang N; Shaik-Dasthagirisaheb YB; LaValley MP; Gibson FC
Mol Oral Microbiol; 2015 Dec; 30(6):438-50. PubMed ID: 25946408
[TBL] [Abstract][Full Text] [Related]
8. Inflammation and tissue loss caused by periodontal pathogens is reduced by interleukin-1 antagonists.
Delima AJ; Karatzas S; Amar S; Graves DT
J Infect Dis; 2002 Aug; 186(4):511-6. PubMed ID: 12195378
[TBL] [Abstract][Full Text] [Related]
9. Oral Administration of Porphyromonas gingivalis Alters the Gut Microbiome and Serum Metabolome.
Kato T; Yamazaki K; Nakajima M; Date Y; Kikuchi J; Hase K; Ohno H; Yamazaki K
mSphere; 2018 Oct; 3(5):. PubMed ID: 30333180
[TBL] [Abstract][Full Text] [Related]
10. Preventive effects of the novel antimicrobial peptide Nal-P-113 in a rat Periodontitis model by limiting the growth of Porphyromonas gingivalis and modulating IL-1β and TNF-α production.
Wang HY; Lin L; Fu W; Yu HY; Yu N; Tan LS; Cheng JW; Pan YP
BMC Complement Altern Med; 2017 Aug; 17(1):426. PubMed ID: 28851350
[TBL] [Abstract][Full Text] [Related]
11. Pharmaceuticals and periodontal diseases.
Genco RJ
J Am Dent Assoc; 1994 Jan; 125 Suppl():11S-19S. PubMed ID: 8294670
[No Abstract] [Full Text] [Related]
12. Experimental periodontitis induced by Porphyromonas gingivalis does not alter the onset or severity of diabetes in mice.
Li H; Yang H; Ding Y; Aprecio R; Zhang W; Wang Q; Li Y
J Periodontal Res; 2013 Oct; 48(5):582-90. PubMed ID: 23317150
[TBL] [Abstract][Full Text] [Related]
13. CXCR4 signaling contributes to alveolar bone resorption in Porphyromonas gingivalis-induced periodontitis in mice.
Nagashima H; Shinoda M; Honda K; Kamio N; Hasuike A; Sugano N; Arai Y; Sato S; Iwata K
J Oral Sci; 2017 Dec; 59(4):571-577. PubMed ID: 29093284
[TBL] [Abstract][Full Text] [Related]
14. The Effects of Antimicrobial Peptide Nal-P-113 on Inhibiting Periodontal Pathogens and Improving Periodontal Status.
Wang H; Ai L; Zhang Y; Cheng J; Yu H; Li C; Zhang D; Pan Y; Lin L
Biomed Res Int; 2018; 2018():1805793. PubMed ID: 29736391
[TBL] [Abstract][Full Text] [Related]
15. Melatonin Receptor Agonists as the "Perioceutics" Agents for Periodontal Disease through Modulation of Porphyromonas gingivalis Virulence and Inflammatory Response.
Zhou W; Zhang X; Zhu CL; He ZY; Liang JP; Song ZC
PLoS One; 2016; 11(11):e0166442. PubMed ID: 27832188
[TBL] [Abstract][Full Text] [Related]
16. Morphometric, histomorphometric, and microcomputed tomographic analysis of periodontal inflammatory lesions in a murine model.
Li CH; Amar S
J Periodontol; 2007 Jun; 78(6):1120-8. PubMed ID: 17539727
[TBL] [Abstract][Full Text] [Related]
17. Differential inflammasome activation by Porphyromonas gingivalis and cholesterol crystals in human macrophages and coronary artery endothelial cells.
Champaiboon C; Poolgesorn M; Wisitrasameewong W; Sa-Ard-Iam N; Rerkyen P; Mahanonda R
Atherosclerosis; 2014 Jul; 235(1):38-44. PubMed ID: 24814648
[TBL] [Abstract][Full Text] [Related]
18. Dual Action of Myricetin on Porphyromonas gingivalis and the Inflammatory Response of Host Cells: A Promising Therapeutic Molecule for Periodontal Diseases.
Grenier D; Chen H; Ben Lagha A; Fournier-Larente J; Morin MP
PLoS One; 2015; 10(6):e0131758. PubMed ID: 26121135
[TBL] [Abstract][Full Text] [Related]
19. Oral infection with Porphyromonas gingivalis induces peri-implantitis in a murine model: Evaluation of bone loss and the local inflammatory response.
Tzach-Nahman R; Mizraji G; Shapira L; Nussbaum G; Wilensky A
J Clin Periodontol; 2017 Jul; 44(7):739-748. PubMed ID: 28453225
[TBL] [Abstract][Full Text] [Related]
20. Efficient synthesis of (+/-)-parasitenone, a novel inhibitor of NF-kappaB.
Saitoh T; Suzuki E; Takasugi A; Obata R; Ishikawa Y; Umezawa K; Nishiyama S
Bioorg Med Chem Lett; 2009 Sep; 19(18):5383-6. PubMed ID: 19666224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
